Please login to the form below

Not currently logged in
Email:
Password:

OSE Immunotherapeutics

This page shows the latest OSE Immunotherapeutics news and features for those working in and with pharma, biotech and healthcare.

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Boehringer Ingelheim has licensed a new checkpoint inhibitor from French biotech OSE Immunotherapeutics in a deal that could be worth more than 1.1bn (around $1.4bn). ... The deal focuses around OSE-172, an anti-SIRP-alpha antibody with potential in

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Iris Pauporté joins OSE Immunotherapeutics. She becomes clinical project director at the French biotech. ... Alain Chatelin, medical director at OSE Immunotherapeutics, said: “ We are very pleased to have Iris join our team. “

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics